Phase II Study of S-1 in Combination with Trastuzumab for HER 2-positive Metastatic Breast Cancer

Aim: We undertook a prospective phase II study to evaluate the efficacy of S-1 plus trastuzumab combination regimen for human epidermal-growth factor receptor-2 (HER2)-positive metastatic breast cancer (MBC). Patients and Methods: HER2-positive MBC patients received oral administration of S-1 (80 mg/m2/day, days 1 to 28, every 6 weeks) and intravenous weekly trastuzumab (2 mg/kg), according to the results of a prior Phase I trial of our group. Results: A total of 28 patients were enrolled and received a median of 3.5 (range 1-10) cycles of treatment. Overall response rate and clinical benefit rate were 53.6% and 75.0%, respectively. Progression-free survival was 30 weeks. With regard to grade 3 and 4 adverse effects, leucopenia, neutropenia, increase in serum alanine aminotransferase, and diarrhea were observed. Conclusion: Combination of S1 and trastuzumab was tolerable and had excellent efficacy with good response and disease control in this trial. Trastuzumab, a humanized monoclonal antibody against the extracellular domain of human epidermal growth factor receptor type-2, has shown high clinical efficacy in combination with cytotoxic agents for HER2-overexpressing breast cancer. After this agent was approved, prognosis of the patients with HER2positive advanced or metastatic disease has become superior to that of estrogen receptor-negative disease (1). According to the Japanese Breast Cancer Society guidelines (2) and National Comprehensive Cancer network guidelines (3) chemotherapy is recommended for advanced or metastatic breast cancer that is refractory to hormonal therapy. The first and second choices of cytotoxic agents are either anthracyclines or taxanes. The options for the third-line or later treatment comprised of capecitabine, S-1, vinorelbine, irinotecan, gemcitabine, and eribulin. For HER2-positive 3583 This article is freely accessible online. Correspondence to: Tsutomu Takashima, MD, Ph.D., Department of Surgical Oncology, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi Abeno Osaka 5458585 Japan. Tel: +81 666453838, Fax: +81 666466450, e-mail: tsutomu-@rd5.so-net.ne.jp

[1]  S. Loibl,et al.  Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. , 2011, European journal of cancer.

[2]  Y. Tokuda,et al.  Post-marketing Safety Evaluation of S-1 in Patients with Inoperable or Recurrent Breast Cancer: Especially in Patients Treated with S-1 + Trastuzumab , 2011, Japanese journal of clinical oncology.

[3]  F. Hara,et al.  Efficacy and Safety of S-1 in Patients with Metastatic Breast Cancer: Retrospective Review in a Single Institution , 2011, Oncology.

[4]  T. Ohmura,et al.  Randomized study of taxane versus TS-1 in women with metastatic or recurrent breast cancer (SELECT BC). , 2010, Japanese journal of clinical oncology.

[5]  H. Imamura,et al.  [A case of luminal B recurrent breast cancer with liver and lymph node metastases successfully treated with combination therapy of S-1 plus trastuzumab]. , 2010, Gan to kagaku ryoho. Cancer & chemotherapy.

[6]  M. Fukuoka,et al.  Synergistic Antitumor Effect of S-1 and HER2-Targeting Agents in Gastric Cancer with HER2 Amplification , 2010, Molecular Cancer Therapeutics.

[7]  M. Okada,et al.  [New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)]. , 2009, Gan to kagaku ryoho. Cancer & chemotherapy.

[8]  A. Ohtsu,et al.  Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. , 2009, The Lancet. Oncology.

[9]  Tomoki Tokugawa,et al.  [A patient with multiple skin metastases from breast cancer responding to S-1 effectively under treatment with trastuzumab]. , 2009, Gan to kagaku ryoho. Cancer & chemotherapy.

[10]  Kazutaka Nakashima,et al.  [A case of paclitaxel and trastuzumab-resistant recurrent breast cancer with liver metastasis responding to S-1]. , 2008, Gan to kagaku ryoho. Cancer & chemotherapy.

[11]  Y. Min,et al.  A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer , 2008, British Journal of Cancer.

[12]  Masahiro Takeuchi,et al.  S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. , 2008, The Lancet. Oncology.

[13]  Yasuo Ohashi,et al.  Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. , 2007, The New England journal of medicine.

[14]  Michael Gnant,et al.  Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Y. Rino,et al.  Antitumor activity of a combination of trastuzumab (Herceptin) and oral fluoropyrimidine S-1 on human epidermal growth factor receptor 2-overexpressing pancreatic cancer. , 2007, Oncology reports.

[16]  K. Sawai,et al.  [A case of multi-drug resistant recurrent breast cancer with multiple bone metastasis responding to TS-1 and trastuzumab]. , 2006, Gan to kagaku ryoho. Cancer & chemotherapy.

[17]  M. J. van de Vijver,et al.  Predicting Early Failure after Adjuvant Chemotherapy in High-Risk Breast Cancer Patients with Extensive Lymph Node Involvement , 2004, Clinical Cancer Research.

[18]  S. Takashima,et al.  A phase II study of S-1 in patients with metastatic breast cancer — A Japanese trial by the S-1 cooperative study group, breast cancer working group , 2004, Breast cancer.

[19]  S. Takashima,et al.  [A late phase II clinical study of S-1 in patients with progressed, refractory breast cancer]. , 2004, Gan to kagaku ryoho. Cancer & chemotherapy.

[20]  S. Culine,et al.  Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. , 2004, European journal of cancer.

[21]  A. Schindler,et al.  Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[23]  M. Sliwkowski,et al.  Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers , 1999, Oncogene.

[24]  G. Hortobagyi,et al.  Treatment of breast cancer. , 1998, The New England journal of medicine.

[25]  J. Sakamoto,et al.  Phase I study of S-1 in combination with trastuzumab for HER2-positive metastatic breast cancer. , 2011, Anticancer research.

[26]  Ross Camidge,et al.  The European Organisation for Research and Treatment of Cancer , 2002 .

[27]  D. Osoba,et al.  Interpreting the significance of changes in health-related quality-of-life scores. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Andrew Bottomley,et al.  EORTC QLQ-C30 Scoring Manual , 1995 .